Outcome and drug | RCTs | Patients in analyses (n) | Rate in active treatment group (%) | Rate in control group (%) | Relative risk (95% CI) | Absolute risk difference (95% CI) | Strength of evidence |
Continence | |||||||
Fesoterodine | 2 | 2465 | 61 | 48.5 | 1.3 (1.1 to 1.5) | 0.13 (0.06 to 0.2) | Low |
Oxybutynin | 4 | 992 | 27 | 16 | 1.7 (1.3 to 2.1) | 0.11 (0.06 to 0.16) | High |
Solifenacin | 5 | 6304 | 39.2 | 28.1 | 1.5 (1.4 to 1.6) | 0.11 (0.06 to 0.16) | High |
Tolterodine | 4 | 3404 | 53.2 | 43.7 | 1.2 (1.1 to 1.4) | 0.09 (0.04 to 0.13) | High |
Trospium | 4 | 2677 | 28.3 | 16.6 | 1.7 (1.5 to 2) | 0.11 (0.08 to 0.14) | High |
Clinically important improvement in incontinence | |||||||
Darifenacin | 3 | 1011 | 48.4 | 33 | 1.3 (1 to 1.5) | 0.12 (0.06 to 0.17) | High |
Fesoterodine | 2 | 1896 | 42 | 32 | 1.3 (1.2 to 1.5) | 0.1 (0.06 to 0.15) | High |
Oxybutynin | 9 | 1244 | 53 | 32 | 1.5 (1.2 to 1.9) | 0.17 (0.1 to 0.24) | Moderate |
Solifenacin | 2 | 1507 | 60.2 | 42 | 1.5 (1 to 2.1) | 0.18 (0.1 to 0.26) | Low |
Tolterodine | 7 | 6119 | 45 | 37 | 1.3 (1.1 to 1.4) | 0.1 (0.04 to 0.15) | High |
Trospium | 2 | 1176 | 32.4 | 25.4 | 1.1 (0.6 to 2) | 0.08 (–0.1 to 0.25) | Low |
آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟